• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

osteoporosis - Articles and news items

UCB and Amgen submit FDA application for Osteoporosis drug

Industry news / 22 July 2016 / Niamh Louise Marriott, Digital Content Producer

UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture…

APAC osteoporosis market to hit $7.7 billion by 2022, says GBI Research

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

The Asia-Pacific (APAC) osteoporosis market is set to grow from $4.5 billion in 2015 to $7.7 billion in 2022, according to GBI Research…

Positive top-line results from Phase III study of romosozumab in osteoporosis

Industry news / 21 March 2016 / Victoria White

The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab…

Positive top-line results for romosozumab FRAME study

Industry news / 23 February 2016 / Victoria White

The Phase III FRAME study evaluated UCB and Amgen’s romosozumab in postmenopausal women with osteoporosis…